Gilead Sciences, Inc. (GILD) Stock Analysis
Is GILD a good investment?
Gilead Sciences, Inc. (GILD) has a Plutrex AI rating of 84.0/100 as of July 10, 2026, indicating a Strong Buy consensus. The stock is not classified as halal-compliant. Key strength: Exceptional profitability with ROE 43.2% and margins significantly outperforming industry across all measures. Main concern: Revenue growth of 4.4% significantly lags industry average of 8.01% indicating potential market share pressures.
Investment Summary
GILD presents a compelling investment opportunity with exceptional profitability metrics (ROE 43.2% vs industry average, gross margin 79.4%) trading at attractive valuation discount (PE 17.09 vs industry 29.44, 41.9% discount). The extraordinary forward EPS growth of 2434.1% combined with improved PEG ratio of 1.41 (down from 1.46) and strong cash position of $9.8 billion creates favorable risk-reward profile. Recent positive news on liver disease treatment and operational readiness for emergency response demonstrates pipeline strength and execution capability.
Key Strengths
- Exceptional profitability with ROE 43.2% and margins significantly outperforming industry across all measures
- Attractive valuation trading at 41.9% discount to industry PE despite superior fundamentals
- Extraordinary forward EPS growth of 2434.1% with improved PEG ratio of 1.41
Key Concerns
- Revenue growth of 4.4% significantly lags industry average of 8.01% indicating potential market share pressures
- Debt-to-equity ratio of 0.89 represents moderate leverage requiring monitoring
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
GILD demonstrates industry-leading fundamentals with ROE of 43.2% indicating exceptional capital efficiency, gross margin of 79.4% showing strong pricing power, and operating margin of 39.3% reflecting operational excellence. The company maintains solid financial health with $9.8 billion cash and free cash flow of $7.9 billion, though debt-to-equity of 0.89 requires monitoring. Valuation is attractive with PE ratio of 17.09 (41.9% discount to industry 29.44) and improved PEG of 1.41. Growth profile shows extraordinary near-term acceleration with 2434.1% forward EPS growth, though revenue growth of 4.4% lags industry average of 8.01%.
News Sentiment
Gilead Sciences is making strategic moves across multiple fronts that showcase its operational excellence and pipeline strength. The biotech giant recently demonstrated its rapid response capabilities by mobilizing emergency donations of its antiviral drug Remdesivir to support Ebola outbreak response efforts, highlighting the company's supply chain agility and global health leadership. On the clinical front, Gilead released encouraging Phase 3 results for its primary biliary cholangitis treatment, strengthening its position in the lucrative liver disease market. However, the company faced a setback when it ended a collaboration with Merck on a lung cancer trial combining Trodelvy with Keytruda, though this appears to be a strategic refocusing rather than a clinical failure. The broader pharmaceutical industry is experiencing an M&A boom as companies rush to expand their pipelines, potentially creating opportunities for Gilead to make strategic acquisitions. Meanwhile, questions persist about whether Gilead's HIV franchise can drive sustainable long-term growth as the market matures. The National AIDS Memorial partnership with the Gilead Foundation represents the company's continued commitment to HIV advocacy and community support, reinforcing its leadership position in this therapeutic area.
Risk Assessment
Primary risks include revenue growth lagging industry peers and moderate debt levels. However, strong cash position of $9.8 billion and exceptional profitability metrics provide downside protection. The extraordinary forward growth projections carry execution risk but are supported by positive clinical trial results.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is GILD a halal stock?
No, Gilead Sciences, Inc. (GILD) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for GILD?
Gilead Sciences, Inc. (GILD) has a Plutrex AI rating of 84.0/100 with a Strong Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is GILD a good investment?
According to Plutrex AI, GILD has a Strong Buy rating (84.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in GILD?
US stocks like GILD can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in GILD?
Plutrex AI identifies the main risks for GILD by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.